nutrients-logo

Journal Browser

Journal Browser

Anticancer Activities of Dietary Phytochemicals: 2nd Edition

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Phytochemicals and Human Health".

Deadline for manuscript submissions: 15 April 2025 | Viewed by 1052

Special Issue Editors


E-Mail Website
Guest Editor
Microbiology, Immunology and Biopharmaceuticals, National Chiayi University, Chiayi City 600, Taiwan
Interests: apoptosis; autophagy; free radical biology and medicine; cancer chemoprevention; anticancer research; preventive medicine; natural product activities; disease prevention research
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Microbiology, Immunology and Biopharmaceuticals, National Chiayi University, Chiayi City 600, Taiwan
Interests: anticancer research; anti-inflammation study; gene regulation; cancer biomarker
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Many diet phytochemicals can play the role of blockers or suppressors through different regulatory mechanisms related to their anti-cancer activities and have cancer chemopreventive effects. Research on the anticancer activities of diet phytochemicals will contribute to cancer treatment and prevention.

We are pleased to announce the launch of our second Special Issue "Anticancer Activities of Dietary Phytochemicals: 2nd Edition". Building on the success of our previous Special Issue, this collection aims to showcase the latest research on the anticancer activities of dietary phytochemicals with a particular emphasis on cancer treatment, cancer prevention, the research and development of dietary phytochemicals as anticancer molecules, their synergistic effects with clinical chemotherapy drugs for anticancer treatment, and the mechanisms of diet phytochemicals in anti-cancer activity. We welcome the submission of research articles that focus on in vitro or in vivo studies covering the effects of crude extracts, extracted fractions, and small molecular, macromolecular, and/or pure compounds, as well as their derivatives or microbial fermentation products, with a focus on their application in the control of various human cancer diseases and their benefits for human health. Review articles and comments are also welcome.

Prof. Dr. Ching-Hsein Chen
Prof. Dr. Yi-Wen Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • phytochemicals
  • dietary
  • nutrients
  • bioactivities
  • isolation and identification
  • cancers
  • cancer cytotoxicity
  • cancer therapy
  • cancer prevention
  • cancer metastasis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 3154 KiB  
Article
Growth of Renal Cancer Cell Lines Is Strongly Inhibited by Synergistic Activity of Low-Dosed Amygdalin and Sulforaphane
by Sascha D. Markowitsch, Thao Pham, Jochen Rutz, Felix K.-H. Chun, Axel Haferkamp, Igor Tsaur, Eva Juengel, Nathalie Ries, Anita Thomas and Roman A. Blaheta
Nutrients 2024, 16(21), 3750; https://doi.org/10.3390/nu16213750 - 31 Oct 2024
Viewed by 779
Abstract
Background: Plant derived isolated compounds or extracts enjoy great popularity among cancer patients, although knowledge about their mode of action is unclear. The present study investigated whether the combination of two herbal drugs, the cyanogenic diglucoside amygdalin and the isothiocyanate sulforaphane (SFN), [...] Read more.
Background: Plant derived isolated compounds or extracts enjoy great popularity among cancer patients, although knowledge about their mode of action is unclear. The present study investigated whether the combination of two herbal drugs, the cyanogenic diglucoside amygdalin and the isothiocyanate sulforaphane (SFN), influences growth and proliferation of renal cell carcinoma (RCC) cell lines. Methods: A498, Caki-1, and KTCTL-26 cells were exposed to low-dosed amygdalin (1 or 5 mg/mL), or SFN (5 µM) or to combined SFN-amygdalin. Tumor growth and proliferation were analyzed by MTT, BrdU incorporation, and clone formation assays. Cell cycle phases and cell cycle-regulating proteins were analyzed by flow cytometry and Western blotting, respectively. The effectiveness of the amygdalin–SFN combination was determined using the Bliss independence model. Results: 1 mg/mL amygdalin or 5 µM SFN, given separately, did not suppress RCC cell growth, and 5 mg/mL amygdalin only slightly diminished A498 (but not Caki-1 and KTCTL-26) cell growth. However, already 1 mg/mL amygdalin potently inhibited growth of all tumor cell lines when combined with SFN. Accordingly, 1 mg/mL amygdalin suppressed BrdU incorporation only when given together with SFN. Clonogenic growth was also drastically reduced by the drug combination, whereas only minor effects were seen under single drug treatment. Superior efficacy of co-treatment, compared to monodrug exposure, was also seen for cell cycling, with an enhanced G0/G1 and diminished G2/M phase in A498 cells. Cell cycle regulating proteins were altered differently, depending on the applied drug schedule (single versus dual application) and the RCC cell line, excepting phosphorylated Akt which was considerably diminished in all three cell lines with maximum effects induced by the drug combination. The Bliss independence analysis verified synergistic interactions between amygdalin and SFN. Conclusions: These results point to synergistic effects of amygdalin and SFN on RCC cell growth and clone formation and Akt might be a relevant target protein. The combined use of low-dosed amygdalin and SFN could, therefore, be beneficial as a complementary option to treat RCC. To evaluate clinical feasibility, the in vitro protocol must be applied to an in vivo model. Full article
(This article belongs to the Special Issue Anticancer Activities of Dietary Phytochemicals: 2nd Edition)
Show Figures

Figure 1

Back to TopTop